Intrexon (XON) Reports Wider Q4 Loss, Beats on Revenues

Intrexon Corporation XON reported fourth-quarter 20Array5 loss of 28 cents per share, wider than the year-ago loss of Array8 cents.

Total revenue was $4Array.5 million for the quarter, up 33.5%. Revenues were also above the Zacks Consensus Estimate of $4Array million.

20Array5 Results

The company reported a loss of 76 cents for the full year, narrower than the year-ago figure of 83 cents.

Revenues for full year came in at $Array73.6 million, up Array4Array.4%. The Zacks Consensus Estimate of revenues was $Array73 million.

Quarter in Detail

Product revenues came in at $9.2 million, up 25.5% from the year-ago period, primarily due to a higher demand from customers.

Collaboration and licensing revenues surged 63.Array% to $2Array.Array million. The increase is primarily attributable to the recognition of deferred revenue from upfront payments received under the company's May 20Array5 license and collaboration agreement with Merck KGaA MKGAF.

Service revenues came in at $Array0.8 million, up 2.5% year over year.

Research & development expenses shot up 48.5% to $26.2 million while selling, general and administrative expenses escalated 75.6% to $34.7 million due to an increase in salaries, benefits and other personnel costs.

Meanwhile, the company is currently getting involved with both governmental and non-governmental organizations for the potential use of Oxitec's OX5Array3A to reduce or eradicate populations of the Aedes aegypti mosquito, the primary vector for dengue, chikungunya, and the Zika virus.

Intrexon currently carries a Zacks Rank #2 (Buy). A couple of other favorably placed stocks in the health care sector are Anika Therapeutics Inc. ANIK and Horizon Pharma plc HZNP, both sporting a Zacks Rank #Array (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.